Latest Regulatory Decisions News

The Virginia Supreme Court has affirmed the State Corporation Commission’s decision to deny a toll rate increase for the Dulles Greenway, owned by Atlas Arteria. Meanwhile, a related federal case alleging constitutional violations will now proceed.

The Takeovers Panel has declined to intervene in the ongoing control tussle for New World Resources, despite concerns over delayed disclosure and contested share acquisitions.

The Takeovers Panel has decided not to proceed with an application challenging Keybridge Capital’s board decisions amid Yowie Group’s takeover bid, citing prior rulings and no unacceptable circumstances.

The ACCC has approved DP World Australia’s acquisition of Silk Logistics, concluding it won’t significantly harm competition in container stevedoring and logistics services. The decision follows a thorough investigation into potential market impacts.

The Takeovers Panel has introduced a gradual lifting of voting restrictions on ARN Media's 6.83% stake in Southern Cross Media, following Sandon Capital's push to influence board control.

Silk Logistics Holdings and DP World Australia have agreed to push back the deadline for their acquisition deal, awaiting a key regulatory decision from the ACCC.

The Takeovers Panel has declined to review its earlier decision on Keybridge Capital's board reshuffle, dismissing Yowie Group's challenge and signaling a firm stance on takeover conduct.

Augustus Minerals has secured a key position in the Mt Kare Gold Project by acquiring ACM Contract Mining PNG Ltd, positioning itself second-in-line for the exploration license in Papua New Guinea.

The Takeovers Panel has declined to find unacceptable circumstances in Keybridge Capital's attempt to alter Yowie Group's board during an ongoing takeover bid, signaling regulatory acceptance of strategic board changes in contested bids.

PainChek has advanced its US regulatory approval process with a positive FDA meeting, setting the stage for a potential market debut of its pain assessment app in late 2025.

Chimeric Therapeutics has secured FDA Fast Track designation for its CHM CDH17 CAR-T therapy targeting gastroenteropancreatic neuroendocrine tumours, accelerating its path toward regulatory approval and patient access.

Smartpay Holdings Limited posted solid FY25 financials with revenue surpassing $104 million, driven by Australian market gains and promising New Zealand pilot progress. The company is advancing its trans-Tasman payments strategy amid regulatory developments.